BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31173268)

  • 21. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
    Okabe S; Tauchi T; Ohyashiki K
    Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
    Gökbuget N; Zugmaier G; Klinger M; Kufer P; Stelljes M; Viardot A; Horst HA; Neumann S; Brüggemann M; Ottmann OG; Burmeister T; Wessiepe D; Topp MS; Bargou R
    Haematologica; 2017 Apr; 102(4):e132-e135. PubMed ID: 28082340
    [No Abstract]   [Full Text] [Related]  

  • 23. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
    Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
    Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
    Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
    Uckun FM; Myers DE; Cheng J; Qazi S
    EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
    Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
    Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
    Dai Q; Liu X; Yang H; Guo S; Wang Y; Peng L; Ye L; Chen L; Lai C; Chen Q; Zhang G; Jiang Y
    Leuk Res; 2018 May; 68():57-61. PubMed ID: 29544133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of an altered immunoglobulin heavy-chain gene rearrangement in the central nervous system in B-precursor acute lymphoblastic leukemia.
    Wasserman R; Felix CA; McKenzie SE; Shane S; Lange B; Finger LR
    Leukemia; 1993 Aug; 7(8):1294-9. PubMed ID: 8350631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
    Wenzinger C; Williams E; Gru AA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):275-288. PubMed ID: 29951888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
    Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
    Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
    Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ph-positive leukemia: a transgenic mouse model.
    Groffen J; Voncken JW; Kaartinen V; Morris C; Heisterkamp N
    Leuk Lymphoma; 1993; 11 Suppl 1():19-24. PubMed ID: 8251894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
    Mishra S; Zhang B; Groffen J; Heisterkamp N
    Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.
    Owaidah TM; Rawas FI; Al Khayatt MF; Elkum NB
    Hematol Oncol Stem Cell Ther; 2008; 1(1):34-7. PubMed ID: 20063526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
    Ramsey LB; Janke LJ; Payton MA; Cai X; Paugh SW; Karol SE; Kamdem Kamdem L; Cheng C; Williams RT; Jeha S; Pui CH; Evans WE; Relling MV
    PLoS One; 2015; 10(8):e0135134. PubMed ID: 26252865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.